oasis semaglutide Low Dose Oral for Overweight Adults (OASIS-4) | NEJM ADA 2026 - Cardiometabolic effects

The people on whom the avatars are based have explicitly consented to their use

It is considered investigational, which is precisely why medical supervision is essential before considering it

Injection site reactions occur in roughly 1.4% to 2.4% of patients using subcutaneous semaglutide, according to clinical trial data

02.02.25 Study found that most people using GLP-1s for weight loss quit within a year Researchers found that 65% of people using GLP-1 drugs to lose weight quit taking them within a year

Early clinical experiences with implanted insulin-producing cells suggest that restoration of functional -cell pools is feasible, but broad implementation will depend on overcoming barriers related to immune protection, standardization of cell manufacturing, and long-term safety and maturation of grafted cells

Open communication about energy changes supports safe, effective treatment